Production of extended release mini-tablets using directly compressible grades of HPMC

References

• Maderuelo C, Zarzuelo A, Lanao JM. (2011). Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release, 154:2–19.
   PubMed Web of Science ®Google Scholar
• Ghimire M, Hodges LA, Band J, O’Mahony B, McInnes FJ, Mullen AB et al. (2010). In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. J Control Release, 147:70–75.
   PubMed Web of Science ®Google Scholar
• Hardy IJ, Cook WG, Melia CD. (2006). Compression and compaction properties of plasticised high molecular weight hydroxypropylmethylcellulose (HPMC) as a hydrophilic matrix carrier. Int J Pharm, 311:26–32.
   PubMed Web of Science ®Google Scholar
• Alderborn G. (2002). Tablet and compaction. In: Aulton’s Pharmaceutics: The science of dosage from design. 2nd edition. Leicester: Churchill Livingstone, 402–423.
   Google Scholar
• Gohel MC, Jogani PD. (2005). A review of co-processed directly compressible excipients. J Pharm Pharm Sci, 8:76–93.
   PubMed Web of Science ®Google Scholar
• Villanova JC, Ayres E, Oréfice RL. (2011). Design of prolonged release tablets using new solid acrylic excipients for direct compression. Eur J Pharm Biopharm, 79:664–673.
   PubMed Web of Science ®Google Scholar
• Wells J. (2002). Pharmaceuticl preformulations: the physiochemical properties of drug substance. In: Aulton’s Pharmaceutics: The science of dosage from design. 2nd edition. Leicester: Churchill Livingstone, 113–138.
   Google Scholar
• Flemming J, Mielck JB. (1995). Requirements for the production of microtablets: suitability of direct-compression excipients estimated from powder characteristics and flow rates. Drug Dev Ind Pharm, 21. 2239–2251.
   Web of Science ®Google Scholar
• Shah R, Tawakkul M, Khan M. (2008). Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech, 9:250–258.
   PubMed Web of Science ®Google Scholar
• Stoltenberg I, Breitkreutz J. (2011). Orally disintegrating mini-tablets (ODMTs)–a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm, 78:462–469.
   PubMed Web of Science ®Google Scholar
• Lopes CM, Lobo JM, Pinto JF, Costa P. (2006). Compressed mini-tablets as a biphasic delivery system. Int J Pharm, 323:93–100.
   PubMed Web of Science ®Google Scholar
• Thomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutcliffe AG. (2009). Minitablets: New modality to deliver medicines to preschool-aged children. Pediatrics, 123:235–238.
   PubMed Web of Science ®Google Scholar
• Spomer N, Klingmann V, Stoltenberg I, Lerch C, Meissner T, Breitkreutz J. (2012). Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child, 97:283–286.
   PubMed Web of Science ®Google Scholar
• Lennartz P, Mielck JB. (1998). Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm, 173:75–85.
   Web of Science ®Google Scholar
• Mohamed F, Saleem R, Roberts M, Shah UU, Seton L, Ford JL. (2010). Hydrocortisone min-tablets for paediatrics. J Pharmacol Pharm, 62:1441.
   Web of Science ®Google Scholar
• Mohamed F, Roberts M, Ford JL, Levina M, Rajabi-Siahboomi AR. The influence of HPMC concentration on release of theophylline or Hydrocortisone from extended-release mini-tablets. Drug Dev Ind Pharm, (In Press).
   Google Scholar
• Kachrimanis K, Petrides M, Malamataris S. (2005). Flow rate of some pharmaceutical diluents through die-orifices relevant to mini-tableting. Int J Pharm, 303:72–80.
   PubMed Web of Science ®Google Scholar
• Debono M, Price JN, Ross RJ. (2009). Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab, 23:221–232.
   PubMed Web of Science ®Google Scholar
• Howlett TA. (1997). An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf), 46:263–268.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Findling RL, Swanson JM. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109:e39-.
   PubMed Web of Science ®Google Scholar
• Heames K, Shah U, Riby P, Blair J, Ford J, (2009). Accuracy of 2.5 mg hydrocortisone doses from quatered 10 mg tablets. Endocr Abstr, 23:OC3.1.
   Google Scholar
• Simons E. (1985). Guideline for the use of Theophylline in children with asthma. Can Med Assoc 132:1011–1012.
   PubMed Web of Science ®Google Scholar
• Stubbs J, Haw C, Dickens G. (2008). Dose form modification – a common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr, 20:616–627.
   PubMed Web of Science ®Google Scholar
• Roberts M, Vellucci D, Mostafa S, Miolane C, Marchaud D. (2012). Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets. Drug Dev Ind Pharm, 38:1068–1076.
   PubMed Web of Science ®Google Scholar
• Jain S. (1999). Mechanical properties of powders for compaction and tableting: an overview. Pharm Sci Technol Today, 2:20–31.
   PubMedGoogle Scholar
• Fell JT, Newton JM. (1968). The tensile strength of lactose tablets. J Pharm Pharmacol, 20:657–659.
   PubMed Web of Science ®Google Scholar
• Espinoza R, Hong E, Villafuerte L. (2000). Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets. Int J Pharm, 201:165–173.
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15:25–35.
   Web of Science ®Google Scholar
• Ford JL, Mitchell K, Rowe P, Armstrong DJ, Elliott PNC, Rostron C, Hogan JE. (1991). Mathematical modelling of drug release from hydroxypropyl methylcellulose matrices: Effect of temperature. Int J Pharm, 71:95–104.
   Web of Science ®Google Scholar
• Ford JL, Rubinstein MH, McCaul F, Hogan JE, Edgar PJ. (1987). Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropyl methylcellulose matrix tablets. Int J Pharm, 40:223–234.
   Web of Science ®Google Scholar
• Moore JW, Flanner HH. (1996). Mathematical comparison of curves with an emphasis on dissolution profiles. Pharmaceut Tech, 20:64–74.
   Google Scholar
• Nokhodchi A, Ford JL, Rowe PH, Rubinstein MH. (1996). The influence of moisture content on the consolidation properties of hydroxypropylmethylcellulose K4M (HPMC 2208). J Pharm Pharmacol, 48:1116–1121.
   PubMed Web of Science ®Google Scholar
• Huang Y, Khanvilkar KH, Moore AD, Hilliard-Lott M. (2003). Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose. Drug Dev Ind Pharm, 29:79–88.
   PubMed Web of Science ®Google Scholar
• Tahara K, Yamamoto K, Nishihata T. (1995). Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose 2910. J Contr Release, 35:59–66.
   Web of Science ®Google Scholar
• Yang L, Fassihi R. (1997). Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric configuration delivery system. Int J Pharm, 155:219–229.
   Web of Science ®Google Scholar
• Fu XC, Wang GP, Liang WQ, Chow MS. (2004). Prediction of drug release from HPMC matrices: effect of physicochemical properties of drug and polymer concentration. J Control Release, 95:209–216.
   PubMed Web of Science ®Google Scholar